Evidence map›Paper›PMID 33176362›Full record

ArticleJournal of the National Cancer Institute2021

State Variation in Low-Dose Computed Tomography Scanning for Lung Cancer Screening in the United States.

Stacey A Fedewa, Ella A Kazerooni, Jamie L Studts, Robert A Smith, Priti Bandi, Ann Goding Sauer, Megan Cotter, Helmneh M Sineshaw, Ahmedin Jemal, Gerard A Silvestri

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07073898 (Population Health Management Approaches to Increase Lung Cancer Screening in Community Health Centers - UG3 Pilot Clinical Trial), which is not on this map. Cited by 132 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 1 pooled it
16.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07073898 nacompletednot on this mapstarted 2025, after this paper: background citation

Population Health Management Approaches to Increase Lung Cancer Screening in Community Health Centers - UG3 Pilot Clinical Trial

TypeinterventionalSponsorUniversity of UtahRan2025 to 2026Enrolled65ConditionsLung CancerArmsRepeated Text Messages (TM+), Conversational Agent (CA), Educational Video, Proactive Patient Navigation (PPN), Reactive Patient Navigation (RPN)
3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 1 synthesis or guideline pooled it, 226 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable Populations.Journal of the National Comprehensive Cancer Network : JNCCN · 2024
    Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Improving lung cancer screening diagnostic efficiency.Current opinion in pulmonary medicine · 2026
    Review
  12. Association of rurality with brain metastasis at initial diagnosis of lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Stacey A FedewaOffice of the Chief and Scientific Medical Officer, Cancer Society, Atlanta, GA, USA.
Ella A KazerooniDepartments of Radiology and Internal Medicine, University of Michigan Medical School, Ann Arbor, MI.
Jamie L StudtsDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0003-3922-3597
Robert A SmithOffice of the Chief and Scientific Medical Officer, Cancer Society, Atlanta, GA, USA.
Priti BandiOffice of the Chief and Scientific Medical Officer, Cancer Society, Atlanta, GA, USA.ORCID 0000-0003-1169-4231
Ann Goding SauerOffice of the Chief and Scientific Medical Officer, Cancer Society, Atlanta, GA, USA.
Megan CotterOffice of the Chief and Scientific Medical Officer, Cancer Society, Atlanta, GA, USA.ORCID 0000-0001-9268-9869
Helmneh M SineshawOffice of the Chief and Scientific Medical Officer, Cancer Society, Atlanta, GA, USA.ORCID 0000-0001-6926-7895
Ahmedin JemalOffice of the Chief and Scientific Medical Officer, Cancer Society, Atlanta, GA, USA.ORCID 0000-0002-0000-4111
Gerard A SilvestriDivision of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC, USA.
American Cancer Society · USMedical University of South Carolina · USUniversity of Colorado Denver · USUniversity of Michigan · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnnual lung cancer screening (LCS) with low-dose chest computed tomography in older current and former smokers (ie, eligible adults) has been recommended since 2013. Uptake has been slow and variable across the United States. We estimated the LCS rate and growth at the national and state level between 2016 and 2018.

methodsThe American College of Radiology's Lung Cancer Screening Registry was used to capture screening events. Population-based surveys, the US Census, and cancer registry data were used to estimate the number of eligible adults and lung cancer mortality (ie, burden). Lung cancer screening rates (SRs) in eligible adults and screening rate ratios with 95% confidence intervals (CI) were used to measure changes by state and year.

resultsNationally, the SR was steady between 2016 (3.3%, 95% CI = 3.3% to 3.7%) and 2017 (3.4%, 95% CI = 3.4% to 3.9%), increasing to 5.0% (95% CI = 5.0% to 5.7%) in 2018 (2018 vs 2016 SR ratio = 1.52, 95% CI = 1.51 to 1.62). In 2018, several southern states with a high lung-cancer burden (eg, Mississippi, West Virginia, and Arkansas) had relatively low SRs (<4%) among eligible adults, whereas several northeastern states with lower lung cancer burden (eg, Massachusetts, Vermont, and New Hampshire) had the highest SRs (12.8%-15.2%). The exception was Kentucky, which had the nation's highest lung cancer mortality rate and one of the highest SRs (13.7%).

conclusionsFewer than 1 in 20 eligible adults received LCS nationally, and uptake varied widely across states. LCS rates were not aligned with lung cancer burden across states, except for Kentucky, which has supported comprehensive efforts to implement LCS.

Indexed as

Early Detection of CancerLung NeoplasmsAdultAgedEducational StatusHumansMass ScreeningTomography, X-Ray ComputedUnited States

Identifiers

PMID33176362
PMCPMC8328984
OpenAlexW3100140293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.